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We would like to oﬀ er some comments on the updated 
meta-analysis on intravenous magnesium sulphate for 
aneurysmal subarachnoid hemorrhage [1], which was 
conducted by Wong and colleagues and published in a 
recent issue of Critical Care.
First, the authors did not mention a (non-blinded) 
random ized placebo-controlled trial conducted by 
Akdemir and colleagues and published in 2009 [2]. 
Although this study would probably not pass Wong and 
colleagues’ method of scrutiny, we believe that it should 
be mentioned alongside two other studies the authors 
described but did not include in the data analysis.
Second, the study by Westermaier and colleagues [3] 
should not be included in the data analysis. Th ese 
authors, in contrast to those of the other included studies 
in which magnesium was used as an add-on therapy, did 
not use nimodipine in any of the included patients. Wong 
and colleagues exclude the study by Schmid-Elsaesser 
and colleagues [4] because nimodipine was not used in 
the magnesium group but omit doing the same for the 
study by Westermaier and colleagues.
Th ird, Figure 3 [1] shows that the number of control 
subjects in ‘Veyna 2002’ was 20. However, in that study, 
the outcome data in the control group were present for 
only 16 patients (4 of the 20 patients were withdrawn 
because study requirements were not met) [5]. 
Accordingly, the risk ratios in Figure 3 should be adjusted.
Fourth, given Wong and colleagues’ deﬁ nition of 
delayed cerebral ischemia, we wonder why the studies of 
Veyna and colleagues [5], Muroi and colleagues [6], and 
their own study in 2006 [7] were not included in Figure 1 
[1]. In the study by Veyna and colleagues [5], the outcome 
measure ‘clinical vaso spasm’ was deﬁ ned as a ‘new focal 
neurological deﬁ cit that could not be accounted for by 
other causes’. Although the time frame in which this was 
scored is not mentioned, this was during the patients’ 
stay in the intensive care unit and therefore would be 
clinically relevant to include in Figure 1 [1]. Th e same 
applies to the outcome measures ‘delayed ischemic 
neurological deﬁ cit’ in the study by Muroi and colleagues 
[6] and ‘symptomatic vasospasm’ in their own study in 
2006 [7].
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We thank Abdo and colleagues for their interest in our 
articles [1,8] and for their comments. We would like to 
oﬀ er the following clariﬁ cations.
First, it is unfortunate that the article by Akdemir and 
colleagues [2] slipped through the established search 
methodology for the journals. Nevertheless, the authors’ 
results on the lack of an eﬀ ect of magnesium sulphate 
infusion on clinical outcome echoed the con clusion of 
our review.
Second, the study by Schmid-Elsaesser and colleagues 
[4] compared magnesium sulphate infusion with nimodi-
pine, the latter of which has an established beneﬁ cial 
eﬀ ect on aneurysmal subarachnoid hemorrhage. Th e 
study by Westermaier and colleagues [3] was trickier in 
mention ing how their cohort of patients employed 
nimodi pine in the Discussion section but not in the 
Results section. Westermaier and colleagues mentioned 
that they did not seek an alternative route of 
administration for oral tablet forms of nimodipine for 
intubated patients but did not mention that they would 
omit the nimodipine oral tablets in good-grade patients. 
Th is actually is the policy in some neuro surgical centers. 
Th e nature of the comparison between magnesium 
sulphate infusion with placebo infusion is also diﬀ erent 
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from that of Schmid-Elsaesser and colleagues [4]. Again, 
the omission of the data of Westermaier and colleagues 
did not alter the conclusion of the review.
Th ird, Veyna and colleagues [5] exposed a problem in 
the earlier study report format, in which numbers of 
patients were not mentioned in each step. Withdrawal 
could mean just the study medications, and the patients 
were assessed for intention-to-treat analysis. If the four 
control patients had been excluded, the result would have 
been the same (Figure 1) [5,6,9].
Fourth, the new deﬁ nition of delayed cerebral ischemia 
included the subsets of patients with asymptomatic 
cerebral infarction [10], which turned out to be an 
important prognostic factor and which earlier studies 
ignored. Lastly, we would like to emphasize that the 
detrimental eﬀ ect of higher-achieved plasma magnesium 
concentrations further supported the results of the 
current meta-analysis [11].
Competing interests
The authors declare that they have no competing interests.
Published: 24 May 2011
References
1. Wong GK, Poon WS, Boet R, Chan MT, Gin T, Ng SC, Zee B: Intravenous 
magnesium sulphate for aneurysmal subarachnoid hemorrhage: an 
updated systemic review and meta-analysis. Crit Care 2011, 15:R52.
2. Akdemir H, Kulaksizogly O, Tucer B, Menku A, Postalci L, Gunaldi O: 
Magnesium sulfate therapy for cerebral vasospasm after aneurysmal 
subarachnoid hemorrhage. Neurosurg Q 2009, 19:35-39.
3. Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, Kunze E, 
Matthies C, Ernestus RI, Solymosi L, Roosen K: Prophylactic intravenous 
magnesium sulfate for treatment of aneurysmal subarachnoid 
hemorrhage: a randomized placebo-controlled, clinical study. Crit Care 
Med 2010, 38:1284-1290.
4. Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ: 
Intravenous magnesium versus nimodipine in the treatment of patients 
with aneurysmal subarachnoid hemorrhage: a randomized study. 
Neurosurgery 2006, 58:1054-1065.
5. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, 
Marrocco A, Thomas AJ, Mitsias PD: Magnesium sulphate therapy after 
aneurysmal subarachnoid hemorrhage. J Neurosurg 2002, 96:510-514.
6. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E: Magnesium sulphate in 
the management of patients with aneurysmal subarachnoid hemorrhage: 
a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008, 
69:33-39.
7. Wong GK, Chan MT, Boet R, Poon WS, Gin T: Intravenous magnesium sulfate 
after aneurysmal subarachnoid hemorrhage: a prospective randomized 
pilot study. J Neurosurg Anesthesiol 2006, 18:142-148.
8. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC; IMASH 
Investigators: Intravenous magnesium sulphate after aneurysmal 
subarachnoid hemorrhage: a multi-center phase III study. Stroke 2010, 
41:921-926.
9. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen 
M, Rinkel GJ; MASH Study Group: Magnesium sulphate in aneurysmal 
subarachnoid hemorrhage. Stroke 2005, 36:1011-1015.
10.  Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijicks EF, Muizelaar JP, 
Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, 
Broderick JP, Drier JP, Roos YB: Defi nition of delayed cerebral ischemia after 
aneurysmal subarachnoid hemorrhage as an outcome event in clinical 
trials and observation studies: proposal of a multidisciplinary research 
group. Stroke 2010, 41:2391-2395.
11. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC: Plasma 
magnesium concentrations and clinical outcomes in aneurysmal 
subarachnoid hemorrhage patients: post-hoc analysis of Intravenous 
Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH) 
Trial. Stroke 2010, 41:1841-1844.
doi:10.1186/cc10221
Cite this article as: Abdo WF, et al.: Intravenous magnesium in subarachnoid 
hemorrhage. Critical Care 2011, 15:427.
Figure 1. Fixed-eff ects model of risk ratio for a favorable outcome at 3 months. A comparison between magnesium sulphate infusion and a 
placebo in patients with aneurysmal subarachnoid hemorrhage is shown. CI, confi dence interval; M-H, Mantel-Haenszel.
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